JPRN-UMIN000024326已完成未知
Effecy and Safety of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors on Atrial Fibrillation - Effecy and Safety of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors on Atrial Fibrillation
Hyogo collage of medicine0 个研究点目标入组 80 人开始时间: 2016年10月7日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Prior history of stroke / transient ischemic attack within 3-month 2. Valvular AF 3. Prior history of cardiac surgery 4. Chronic kidney disease (eGFR <30)
研究者
相似试验
已完成
不适用
Efficacy and safety of sodium-glucose cotransporter-2 inhibitor in patients with type 2 diabetesType 2 diabetes mellitusJPRN-UMIN000017625Department of Cardiology, Fukuoka University Hospital.50
招募中
不适用
Efficacy and safety of sodium-glucose co-transporter (SGLT2) inhibitor in diabetic patients with chronic liver diseaseDiabetic patients with chronic liver diseaseJPRN-UMIN000035015Kitasato University School of Medicine100
招募中
不适用
Efficacy and safety of sodium-glucose co-transporter (SGLT2) inhibitor in diabetic patients post renal transplantatioDiabetic patients after kidney transplantJPRN-UMIN000033628Tokyo Women's Medical University School of Medicine15
已完成
不适用
Effect of sodium-dependent glucose co-transporter 2(SGLT2) inhibitors on muscle strength in patients with type 2 diabetes mellitustype 2 diabetes mellitusJPRN-UMIN000018367Ise Red Cross Hospital Department of Metabolic Diseases30
尚未招募
不适用
The efficacy of sodium-dependent glucose co-transporter 2(SGLT2) inhibitors for pericardial fat in the type 2 diabetes patientsType 2 diabetes patients with pericardial fat is more than 125 mlJPRN-UMIN000020200ational Hospital Organization Takasaki General Medical Center30